**Core Concept**
D1C stands for Disseminated Intravascular Coagulation, a serious disorder in which the proteins responsible for blood clotting become overactive and form unwanted clots throughout the body. In the context of Acute Myeloid Leukemia (AML), D1C is a well-known complication associated with certain subtypes.

**Why the Correct Answer is Right**
In AML, the promyelocytic subtype (M3) is characterized by the presence of abnormal promyelocytes that produce excessive amounts of tissue factor, a potent activator of the coagulation cascade. This leads to the formation of thrombi in small blood vessels, resulting in disseminated intravascular coagulation (D1C). The pathophysiology of D1C in M3 AML is closely linked to the release of granules from the abnormal promyelocytes, which contain tissue factor and other procoagulant substances.

**Why Each Wrong Option is Incorrect**
* **Option A:** Monocytic (M5) AML is associated with a higher risk of bleeding due to the production of inhibitors of coagulation, such as tissue plasminogen activator, rather than a prothrombotic state.
* **Option C:** Erythrocytic (M6) AML is primarily characterized by the proliferation of erythroid precursors and is not typically associated with D1C.
* **Option D:** Megakaryocytic (M7) AML is associated with thrombocytosis and an increased risk of thrombotic events, but D1C is not a characteristic feature of this subtype.

**Clinical Pearl / High-Yield Fact**
It's essential to recognize that D1C can occur in other subtypes of AML as well, but the association with M3 AML is particularly well-established. The diagnosis of D1C in AML requires a high index of suspicion and may involve laboratory tests, including coagulation studies and imaging of the lungs and other organs.

**✓ Correct Answer: B. Promyelocytic (M3)**